NCT04758325 The Sarcoma Biology and Outcome Project
| NCT ID | NCT04758325 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Prof. Dr. Richard F Schlenk |
| Condition | Sarcoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2019-07-23 |
| Primary Completion | 2030-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2019-07-23 with a primary completion date of 2030-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
SarcBOP - An interdisciplinary and translational registry SarcBOP aims to establish a database that integrates every aspect possibly relevant to sarcoma treatment and research. SarcBOP thus will not be limited to specific questions or patient groups, but instead will build a comprehensive database including clinical, pathologic, and radiologic information, multi-layered molecular data, and patient-reported outcomes, combined with a dedicated biobank for tissue samples and liquid biopsies. As the study integrates seamlessly with the clinical activities of the Heidelberg Sarcoma Center, the Molecular Diagnostics Program of NCT Heidelberg, including the NCT/DKTK MASTER Program, and with the NCT Trial Center, including the PMO Clinical Trials Program, SarcBOP will generate a comprehensive and continuously growing resource for clinicians, researchers, and, finally, patients.
Eligibility Criteria
Inclusion Criteria: * Suspected or proven diagnosis of soft-tissue or bone sarcoma (STBS) * Age ≥12 years * Ability to understand nature and individual consequences of the registry * Written informed consent * Subjects who are physically or mentally capable of giving consent Exclusion Criteria: • Severe neurological or psychiatric disorder interfering with the ability to give written informed consent
Contact & Investigator
Richard F. Schlenk, Prof.Dr.med
PRINCIPAL INVESTIGATOR
National Center for Tumour Disease
Frequently Asked Questions
Who can join the NCT04758325 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Sarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04758325 currently recruiting?
Yes, NCT04758325 is actively recruiting participants. Contact the research team at richard.schlenk@med.uni-heidelberg.de for enrollment information.
Where is the NCT04758325 trial being conducted?
This trial is being conducted at Heidelberg, Germany.
Who is sponsoring the NCT04758325 clinical trial?
NCT04758325 is sponsored by Prof. Dr. Richard F Schlenk. The principal investigator is Richard F. Schlenk, Prof.Dr.med at National Center for Tumour Disease. The trial plans to enroll 3,000 participants.